Third Quarter 2025 Earnings Presentation November 6, 2025 Disclaimer This Presentation contains certain forward-looking statements. These statements may relate to, but are not limited to, expectations of future operating results or financial performance of The Beauty Health Company (the "Company"), capital expenditures, the introduction of new products, market strategy and the ability to execute certain strategic initiatives. Some of the forward-looking statements can be identified by the use of forward- lo ...

Financial Performance - Sales increased by 8.6% to $513.7 million in Q3 2025, compared to $472.9 million in Q3 2024[7] - Organic sales grew 11.5% year-over-year[7] - Acquisition sales contributed $18.4 million to total sales[7] - Net income increased 2.5% to $21.6 million for the third quarter, compared to $21.1 million for the third quarter of 2024[7] - Earnings per diluted share increased to $1.31, based on 16.5 million diluted shares, compared to $1.27 in Q3 2024, based on 16.6 million diluted shares[7] - Cash flow from operating activities increased 23.1% to $34.9 million, compared to $28.3 million in Q3 2024[7] - Free Cash Flow increased 15.4% to $28.1 million, compared to $24.4 million in Q3 2024[7] - Adjusted EBITDA was $56.5 million, compared to $52.4 million for the third quarter of 2024[7] - Adjusted EBITDA margin was 11.0%, compared to 11.1% respectively[7] Strategic Actions - The company closed one acquisition during the third quarter and two subsequent to quarter end[7]

BILL NYSE BILL Investor Deck Nov 2025 Safe harbor This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are statements other than statements of historical facts, and statements in the future tense. Forward-looking statements are based on our expectations as of the date of this presentation and are subject to a number of risks, uncertainties and assumptions, many of which involve factors or circumstances that are beyond our con ...

Financial Performance - Solventum's total sales reached $2,096 million, with a reported increase of 0.7% year-over-year and an organic increase of 2.7% year-over-year[12] - MedSurg segment net sales were $1,206 million, reflecting a reported increase of 2.1% and an organic increase of 1.1% year-over-year[13, 17] - Dental Solutions segment net sales were $340 million, with a reported increase of 8.4% and an organic increase of 6.5% year-over-year[12, 24] - Health Information Systems segment net sales were $345 million, showing a reported increase of 5.9% and an organic increase of 5.6% year-over-year[12, 29] - Purification & Filtration segment net sales were $128 million, a reported decrease of 28.7% but an organic increase of 6.4% year-over-year, representing two months of sales before divestiture[12, 34] Profitability and Cash Flow - The company's GAAP operating margin was 80.6%, while the non-GAAP operating margin was 20.6%[13] - GAAP EPS was $7.22, and non-GAAP EPS was $1.50[13] - Cash from operations was $75 million, and free cash flow was negative $22 million[13] Guidance - The company expects organic sales growth of +2.0% to +3.0%, increasing to the high-end of range, or +2.5% to +3.5% excluding ~50bps of SKU-exit impact[39] - Adjusted EPS is expected to be $5.98 to $6.08, versus a prior range of $5.88 - $6.03[39] - Free cash flow is reduced to $150 million to $250 million from $450 million to $550 million due to the Purification & Filtration divestiture impact[39] - Net interest expense is estimated to be ~$360 million, with total non-operating expense around ~$400 million[40] Strategic Actions - The company completed the sale of the Purification & Filtration segment for approximately $4 billion, generating net proceeds of approximately $3.6 billion, with $2.7 billion used for debt reduction[34]

Earnings Presentation November 6, 2025 NYSE: PAR partech.com Q3 2025 Forward-Looking Statements. This presentation contains forward-looking statements made pursuant to the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934, as amended, Section 27A of the Securities Act of 1933, as amended, and the Private Securities Litigation Reform Act of 1995, and the accuracy of such statements is necessarily subject to risks, uncertainties and assumptions as to future events that may not prove ...

Business Overview Third Quarter 2025 November 2025 The Backbone for Connected Commerce Safe Harbor This presentation has been prepared by VTEX ("we," "us," "our," "VTEX" or the "Company"). This presentation may contain forward-looking statements relating to such matters as continued growth prospects for the Company, industry trends and product and technology initiatives. These statements are based on currently available information and our current assumptions, expectations and projections about future event ...

Quarterly Earnings Supplement Q3 2025 Total Subscription Revenue Growth Product Offerings Subscription Segment Trupanion Core North America Other Subscription Products North America PHI Direct Furkin Chewy Aflac Other Subscription Products Europe PetExpert* (Czechia, Slovakia, Belgium, Poland) Smart Paws (Germany, Switzerland) Trupanion (Germany, Switzerland) Other Business Segment Pets Best Veteran Affairs Service Dog Program Legacy Worksite Benefits (Corporate & Veterinary Hospital) *Managing General Agen ...

Grow with Ginkgo Q3 2025 Update & Business Review November 6, 2025 Property of Ginkgo Bioworks — 1 Q2 2025 UPDATE & BUSINESS REVIEW Disclaimer FORWARD-LOOKING STATEMENTS This presentation, the conference call and webcast contain certain forward-looking statements within the meaning of the federal securities laws, including statements regarding our plans, including with respect to technology adaptations to meet our customers' needs, strategies, including with respect to our current expectations, operations a ...

Financial Performance - H&R Block announced a 12% increase to its quarterly dividend in August[28] - The company repurchased 7.9 million shares for $400 million, retiring approximately 6% of outstanding shares[29] - H&R Block reaffirms its FY26 outlook with revenue projected between $3.875 billion and $3.895 billion, and adjusted EPS between $4.85 and $5.00[33] - The company anticipates an effective tax rate of approximately 25% for FY26[33] Strategic Initiatives - H&R Block is finalizing tax season plans, incorporating learnings from the previous year[12] - The company focuses on strengthening marketing messaging, personalizing experiences, and optimizing the sales funnel[15] - H&R Block aims to enhance the client experience in retail and DIY channels, reducing friction and increasing conversion from marketing demand[15] - Key products like Second Look, AI Tax Assist, Tax Pro Review, and Spruce are being leveraged to deliver value and differentiation[15] Market Focus - H&R Block is prioritizing growth among more complex, higher lifetime value filers[53] - The company aims to meet customers where they are, both digitally and in person, combining trusted human expertise with innovation[72]

3Q25 Earnings Presentation PCRX | November 2025 Forward-looking statements and where to find additional information Any statements in this presentation about Pacira's future expectations, plans, trends, outlook, projections and prospects, and other statements containing the words "anticipate," "believe," "can," "could," "estimate," "expect," "intend," "may," "plan," "project," "should," "will," "would," and similar expressions, constitute forward-looking statements within the meaning of Section 21E of the S ...